

# Hedy L Kindler

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5005545/publications.pdf>

Version: 2024-02-01

35  
papers

1,782  
citations

361413

20  
h-index

395702

33  
g-index

35  
all docs

35  
docs citations

35  
times ranked

2740  
citing authors

#	ARTICLE	IF	CITATIONS
1	Diet- and Lifestyle-Based Prediction Models to Estimate Cancer Recurrence and Death in Patients With Stage III Colon Cancer (CALGB 89803/Alliance). <i>Journal of Clinical Oncology</i> , 2022, 40, 740-751.	1.6	20
2	Marital Status, Living Arrangement, and Cancer Recurrence and Survival in Patients with Stage III Colon Cancer: Findings from CALGB 89803 (Alliance). <i>Oncologist</i> , 2022, 27, e494-e505.	3.7	5
3	The role of imaging in diagnosis and management of malignant peritoneal mesothelioma: a systematic review. <i>Abdominal Radiology</i> , 2022, 47, 1725-1740.	2.1	4
4	Anetumab ravtansine versus vinorelbine in patients with relapsed, mesothelin-positive malignant pleural mesothelioma (ARCS-M): a randomised, open-label phase 2 trial. <i>Lancet Oncology</i> , The, 2022, 23, 540-552.	10.7	25
5	Medical and Surgical Care of Patients With Mesothelioma and Their Relatives Carrying Germline BAP1 Mutations. <i>Journal of Thoracic Oncology</i> , 2022, 17, 873-889.	1.1	44
6	Overall Survival Results From the POLO Trial: A Phase III Study of Active Maintenance Olaparib Versus Placebo for Germline BRCA-Mutated Metastatic Pancreatic Cancer. <i>Journal of Clinical Oncology</i> , 2022, 40, 3929-3939.	1.6	66
7	Heterogeneity in PD-L1 expression in malignant peritoneal mesothelioma with systemic or intraperitoneal chemotherapy. <i>British Journal of Cancer</i> , 2021, 124, 564-566.	6.4	18
8	Race, Income, and Survival in Stage III Colon Cancer: CALGB 89803 (Alliance). <i>JNCI Cancer Spectrum</i> , 2021, 5, pkab034.	2.9	4
9	Systemic Therapy for Mesothelioma: Turning the Corner. <i>JCO Oncology Practice</i> , 2021, , OP2100785.	2.9	2
10	Clinical Assessment of 5-Fluorouracil/Leucovorin, Nab-Paclitaxel, and Irinotecan (FOLFIRABRAX) in Untreated Patients with Gastrointestinal Cancer Using <i>UGT1A1</i> Genotype-Guided Dosing. <i>Clinical Cancer Research</i> , 2020, 26, 18-24.	7.0	10
11	Clinical Response of Live-Attenuated, <i>Listeria monocytogenes</i> Expressing Mesothelin (CRS-207) with Chemotherapy in Patients with Malignant Pleural Mesothelioma. <i>Clinical Cancer Research</i> , 2019, 25, 5787-5798.	7.0	72
12	Inherited predisposition to malignant mesothelioma and overall survival following platinum chemotherapy. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2019, 116, 9008-9013.	7.1	108
13	A <i>UGT1A1</i> genotype-guided dosing study of modified FOLFIRINOX in previously untreated patients with advanced gastrointestinal malignancies. <i>Cancer</i> , 2019, 125, 1629-1636.	4.1	27
14	Marine $\omega$ -3 Polyunsaturated Fatty Acid and Fish Intake after Colon Cancer Diagnosis and Survival: CALGB 89803 (Alliance). <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2018, 27, 438-445.	2.5	52
15	Reply to D. de Fonseca et al. <i>Journal of Clinical Oncology</i> , 2018, 36, 2746-2747.	1.6	0
16	Nut Consumption and Survival in Patients With Stage III Colon Cancer: Results From CALGB 89803 (Alliance). <i>Journal of Clinical Oncology</i> , 2018, 36, 1112-1120.	1.6	50
17	Treatment of Malignant Pleural Mesothelioma: American Society of Clinical Oncology Clinical Practice Guideline. <i>Journal of Clinical Oncology</i> , 2018, 36, 1343-1373.	1.6	324
18	Current and Future Management of Malignant Mesothelioma: A Consensus Report from the National Cancer Institute Thoracic Malignancy Steering Committee, International Association for the Study of Lung Cancer, and Mesothelioma Applied Research Foundation. <i>Journal of Thoracic Oncology</i> , 2018, 13, 1655-1667.	1.1	85

#	ARTICLE	IF	CITATIONS
19	Grain Intake and Clinical Outcome in Stage III Colon Cancer: Results From CALGB 89803 (Alliance). JNCI Cancer Spectrum, 2018, 2, pky017.	2.9	10
20	Overall survival and clinical characteristics of BRCA mutation carriers with stage I/II pancreatic cancer. British Journal of Cancer, 2017, 116, 697-702.	6.4	70
21	The IASLC Mesothelioma Staging Project: Proposals for Revisions of the T Descriptors in the Forthcoming Eighth Edition of the TNM Classification for Pleural Mesothelioma. Journal of Thoracic Oncology, 2016, 11, 2089-2099.	1.1	139
22	The IASLC Mesothelioma Staging Project: Proposals for the M Descriptors and for Revision of the TNM Stage Groupings in the Forthcoming (Eighth) Edition of the TNM Classification for Mesothelioma. Journal of Thoracic Oncology, 2016, 11, 2112-2119.	1.1	172
23	Unique fractal evaluation and therapeutic implications of mitochondrial morphology in malignant mesothelioma. Scientific Reports, 2016, 6, 24578.	3.3	32
24	Specimen weight and volume: important predictors of survival in malignant pleural mesothelioma. European Journal of Cardio-thoracic Surgery, 2016, 49, 1642-1647.	1.4	21
25	Phase I Study of Apatolisib (GDC-0980), Dual Phosphatidylinositol-3-Kinase and Mammalian Target of Rapamycin Kinase Inhibitor, in Patients with Advanced Solid Tumors. Clinical Cancer Research, 2016, 22, 2874-2884.	7.0	103
26	Generalizability of Trial Results to Elderly Medicare Patients With Advanced Solid Tumors (Alliance) Tj ETQq0 0 0 rgBT/Overlock 10 Tf 50	8.3	27
27	Coffee Intake, Recurrence, and Mortality in Stage III Colon Cancer: Results From CALGB 89803 (Alliance). Journal of Clinical Oncology, 2015, 33, 3598-3607.	1.6	60
28	Sugar-Sweetened Beverage Intake and Cancer Recurrence and Survival in CALGB 89803 (Alliance). PLoS ONE, 2014, 9, e99816.	2.5	65
29	Considering the role of radiation therapy for gastrointestinal stromal tumor. OncoTargets and Therapy, 2014, 7, 713.	2.0	16
30	25-Hydroxyvitamin D Levels and Survival in Advanced Pancreatic Cancer: Findings From CALGB 80303 (Alliance). Journal of the National Cancer Institute, 2014, 106, .	6.3	28
31	MET and PI3K/mTOR as a Potential Combinatorial Therapeutic Target in Malignant Pleural Mesothelioma. PLoS ONE, 2014, 9, e105919.	2.5	52
32	A randomized pilot phase I study of modified carcinoembryonic antigen (CEA) peptide (CAPI-6D)/montanide/GM-CSF-vaccine in patients with pancreatic adenocarcinoma. , 2013, 1, 8.		30
33	Phase II Study of Pemetrexed Plus Gemcitabine in Advanced Pancreatic Cancer. American Journal of Cancer, 2005, 4, 185-191.	0.4	1
34	9-Aminocamptothecin (9-AC) given as a 120-hour continuous infusion in patients with advanced adenocarcinomas of the stomach and gastroesophageal junction: A phase II trial of the University of Chicago phase II consortium. Investigational New Drugs, 2004, 22, 323-327.	2.6	6
35	Moving beyond chemotherapy: novel cytostatic agents for malignant mesothelioma. Lung Cancer, 2004, 45, S125-S127.	2.0	34